Osteoporosis affects an estimated 75 million people in Europe, US and Japan with more than 180,000 patients suffer fragility fractures in the UK alone each year, at a cost of around £2 billion to the NHS.
Teriparatide, an excellent recent addition to the range of drugs used for the treatment of osteoporosis, but it currently needs to be injected every day. The consortium will exploit a recent discovery in nanotechnology to develop a nasal spray formulation of teriparatide that is easy to administer by patients and provides optimal drug plasma levels to enhance efficacy.
The Technology Strategy Board and the Engineering and Physical Sciences Research Council (EPSRC) are supporting this project with grant funding as part of their investment in nanoscale technology-enabled solutions in healthcare.
Critical Pharmaceuticals CriticalSorb™ nanotechnology is a best in class absorption promoter that enables the nasal delivery of biological and challenging small molecule drugs. Biological drugs represent a $100 billion market, and yet nearly all need to be administered by frequent injection. CriticalSorb™ has the potential to transform the delivery of biological drugs by enabling non-invasive delivery that would be strongly preferred by patients. Critical Pharmaceuticals lead product is a nasal formulation of human growth hormone (CP024) that uses CriticalSorb™ and is currently in phase 1 clinical development.
Critical Pharmaceuticals is an emerging biotechnology company. CEO, Dr Gareth King, said: “We are excited about working with internationally-recognised clinicians and scientists at The University of Nottingham and Nottingham University Hospitals NHS Trust to rapidly develop this highly innovative formulation of teriparatide and look forward to the day we can offer it as an attractive alternative to daily injection for the many older people living with osteoporosis”.
The University of Nottingham has world-leading capabilities in clinical and basic research in osteoporosis, geriatric care, bone pathophysiology and medical imaging. The use of University expertise for imaging drug deposition and clearance will greatly enhance the development of this formulation. This project will draw on interdisciplinary collaborative research from international experts Dr Richard Pearson (Division of Orthopaedic & Accident Surgery), Professor Alan Perkins (Division of Radiological and Imaging Sciences) and Professor Tahir Masud (Geriatric Medicine).) and (Geriatric Medicine).
Dr Richard Pearson, Senior Research Fellow in The University of Nottingham’s Faculty of Medicine and Health Sciences, said “I’m delighted to collaborate on this project that will enable us to further develop the world-leading research and development capability at The University of Nottingham for the evaluation of drugs for osteoporosis and to work closely with Critical Pharmaceuticals scientists on the development of an exciting new therapy for this debilitating disease”., Senior Research Fellow in The University of Nottingham’s Faculty of Medicine and Health Sciences, said “I’m delighted to collaborate on this project that will enable us to further develop the world-leading research and development capability at The University of Nottingham for the evaluation of drugs for osteoporosis and to work closely with Critical Pharmaceuticals scientists on the development of an exciting new therapy for this disease”.
For up to the minute media alerts, follow us on Twitter
Notes to editors:
Critical Pharmaceuticals is a Nottingham UK-based biotechnology company developing a pipeline of unique biological drug products utilizing its proprietary drug delivery technologies. These technologies enable the development of sustained release injectable depot and nasal delivery of proteins and peptides and small molecular weight drugs. As well as developing its own pipeline, Critical Pharmaceuticals works in partnership with other pharmaceutical and biotechnology companies to enhance the delivery of their novel drug products. For more information visit www.criticalpharmaceuticals.com.
The Technology Strategy Board is a business-led government body which works to create economic growth by ensuring that the UK is a global leader in innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org
The University of Nottingham, described by The Sunday Times University Guide 2011 as ‘the embodiment of the modern international university’, has 42,000 students at award-winning campuses in the United Kingdom, China and Malaysia. It is also the most popular university in the UK by 2012 application numbers, and ‘the world’s greenest university’. It is ranked in the UK’s Top 10 and the World’s Top 75 universities by the Shanghai Jiao Tong (SJTU) and the QS World University Rankings.
More than 90 per cent of research at The University of Nottingham is of international quality, according to the most recent Research Assessment Exercise. The University aims to be recognised around the world for its signature contributions, especially in global food security, energy & sustainability, and health. The University won a Queen’s Anniversary Prize for Higher and Further Education in 2011, for its research into global food security.
More information is available from Dr Gareth King, CEO, Critical Pharmaceuticals, on +44 (0)115 882 0100, [email protected]
Lindsay Brooke – Media Relations Manager
Email: [email protected] Phone: +44 (0)115 951 5751 Location: King’s Meadow Campus